Search

Your search keyword '"Gounder, Mrinal M"' showing total 481 results
Start Over Author "Gounder, Mrinal M"
481 results on '"Gounder, Mrinal M"'

1. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial

Author

Gounder, Mrinal M, Razak, Albiruni Abdul, Somaiah, Neeta, Chawla, Sant, Martin-Broto, Javier, Grignani, Giovanni, Schuetze, Scott M, Vincenzi, Bruno, Wagner, Andrew J, Chmielowski, Bartosz, Jones, Robin L, Riedel, Richard F, Stacchiotti, Silvia, Loggers, Elizabeth T, Ganjoo, Kristen N, Le Cesne, Axel, Italiano, Antoine, del Muro, Xavier Garcia, Burgess, Melissa, Piperno-Neumann, Sophie, Ryan, Christopher, Mulcahy, Mary F, Forscher, Charles, Penel, Nicolas, Okuno, Scott, Elias, Anthony, Hartner, Lee, Philip, Tony, Alcindor, Thierry, Kasper, Bernd, Reichardt, Peter, Lapeire, Lore, Blay, Jean-Yves, Chevreau, Christine, Morales, Claudia Maria Valverde, Schwartz, Gary K, Chen, James L, Deshpande, Hari, Davis, Elizabeth J, Nicholas, Garth, Gröschel, Stefan, Hatcher, Helen, Duffaud, Florence, Herráez, Antonio Casado, Beveridge, Roberto Diaz, Badalamenti, Giuseppe, Eriksson, Mikael, Meyer, Christian, von Mehren, Margaret, Van Tine, Brian A, Götze, Katharina, Mazzeo, Filomena, Yakobson, Alexander, Zick, Aviad, Lee, Alexander, Gonzalez, Anna Estival, Napolitano, Andrea, Dickson, Mark A, Michel, Dayana, Meng, Changting, Li, Lingling, Liu, Jianjun, Ben-Shahar, Osnat, Van Domelen, Dane R, Walker, Christopher J, Chang, Hua, Landesman, Yosef, Shah, Jatin J, Shacham, Sharon, Kauffman, Michael G, and Attia, Steven

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Genetics, Patient Safety, Clinical Research, 6.1 Pharmaceuticals, Cancer, Child, Double-Blind Method, Humans, Hydrazines, Liposarcoma, Triazoles, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeAntitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed with selinexor. We evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose sarcoma progressed on approved agents.MethodsSEAL was a phase II-III, multicenter, randomized, double-blind, placebo-controlled study. Patients age 12 years or older with advanced DD-LPS who had received two-five lines of therapy were randomly assigned (2:1) to selinexor (60 mg) or placebo twice weekly in 6-week cycles (crossover permitted). The primary end point was progression-free survival (PFS). Patients who received at least one dose of study treatment were included for safety analysis (ClinicalTrials.gov identifier: NCT02606461).ResultsTwo hundred eighty-five patients were enrolled (selinexor, n = 188; placebo, n = 97). PFS was significantly longer with selinexor versus placebo: hazard ratio (HR) 0.70 (95% CI, 0.52 to 0.95; one-sided P = .011; medians 2.8 v 2.1 months), as was time to next treatment: HR 0.50 (95% CI, 0.37 to 0.66; one-sided P < .0001; medians 5.8 v 3.2 months). With crossover, no difference was observed in overall survival. The most common treatment-emergent adverse events of any grade versus grade 3 or 4 with selinexor were nausea (151 [80.7%] v 11 [5.9]), decreased appetite (113 [60.4%] v 14 [7.5%]), and fatigue (96 [51.3%] v 12 [6.4%]). Four (2.1%) and three (3.1%) patients died in the selinexor and placebo arms, respectively. Exploratory RNA sequencing analysis identified that the absence of CALB1 expression was associated with longer PFS with selinexor compared with placebo (median 6.9 v 2.2 months; HR, 0.19; P = .001).ConclusionPatients with advanced, refractory DD-LPS showed improved PFS and time to next treatment with selinexor compared with placebo. Supportive care and dose reductions mitigated side effects of selinexor. Prospective validation of CALB1 expression as a predictive biomarker for selinexor in DD-LPS is warranted.

Published
2022

3. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

Author

Gounder, Mrinal M, Agaram, Narasimhan P, Trabucco, Sally E, Robinson, Victoria, Ferraro, Richard A, Millis, Sherri Z, Krishnan, Anita, Lee, Jessica, Attia, Steven, Abida, Wassim, Drilon, Alexander, Chi, Ping, Angelo, Sandra P D’, Dickson, Mark A, Keohan, Mary Lou, Kelly, Ciara M, Agulnik, Mark, Chawla, Sant P, Choy, Edwin, Chugh, Rashmi, Meyer, Christian F, Myer, Parvathi A, Moore, Jessica L, Okimoto, Ross A, Pollock, Raphael E, Ravi, Vinod, Singh, Arun S, Somaiah, Neeta, Wagner, Andrew J, Healey, John H, Frampton, Garrett M, Venstrom, Jeffrey M, Ross, Jeffrey S, Ladanyi, Marc, Singer, Samuel, Brennan, Murray F, Schwartz, Gary K, Lazar, Alexander J, Thomas, David M, Maki, Robert G, Tap, William D, Ali, Siraj M, and Jin, Dexter X

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Genetics, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Biotechnology, Clinical Research, Human Genome, Genetic Testing, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Biomarkers, Tumor, Bone Neoplasms, Genomics, Humans, Mutation, Osteosarcoma, Prospective Studies, Sarcoma
Abstract

There are more than 70 distinct sarcomas, and this diversity complicates the development of precision-based therapeutics for these cancers. Prospective comprehensive genomic profiling could overcome this challenge by providing insight into sarcomas' molecular drivers. Through targeted panel sequencing of 7494 sarcomas representing 44 histologies, we identify highly recurrent and type-specific alterations that aid in diagnosis and treatment decisions. Sequencing could lead to refinement or reassignment of 10.5% of diagnoses. Nearly one-third of patients (31.7%) harbor potentially actionable alterations, including a significant proportion (2.6%) with kinase gene rearrangements; 3.9% have a tumor mutational burden ≥10 mut/Mb. We describe low frequencies of microsatellite instability (

Published
2022

4. Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments

Author

Stacchiotti, Silvia, Maria Frezza, Anna, Demetri, George D., Blay, Jean-Yves, Bajpai, Jyoti, Baldi, Giacomo G., Baldini, Elizabeth H., Benjamin, Robert S., Bonvalot, Sylvie, Bovée, Judith V.M.G., Callegaro, Dario, Casali, Paolo G., D'Angelo, Sandra P., Davis, Elizabeth J., Dei Tos, Angelo P., Demicco, Elizabeth G., Desai, Jayesh, Dileo, Palma, Eriksson, Mikael, Gelderblom, Hans, George, Suzanne, Gladdy, Rebecca A., Gounder, Mrinal M., Gupta, Abha A., Haas, Rick, Hayes, Andrea, Hohenberger, Peter, Jones, Kevin B., Jones, Robin L., Kasper, Bernd, Kawai, Akira, Kirsch, David G., Kleinerman, Eugenie S., Le Cesne, Axel, Maestro, Roberta, Martin Broto, Javier, Maki, Robert G., Miah, Aisha B., Palmerini, Emanuela, Patel, Shreaskumar R., Raut, Chandrajit P., Razak, Albiruni R.A., Reed, Damon R., Rutkowski, Piotr, Sanfilippo, Roberta G., Sbaraglia, Marta, Schaefer, Inga-Marie, Strauss, Dirk C., Strauss, Sandra J., Tap, William D., Thomas, David M., Trama, Annalisa, Trent, Jonathan C., van der Graaf, Winette T.A., van Houdt, Winan J., von Mehren, Margaret, Wilky, Breelyn A., Fletcher, Christopher D.M., Gronchi, Alessandro, Miceli, Rosalba, and Wagner, Andrew J.

Published
2022
Full Text
View/download PDF

7. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

Author

Nacev, Benjamin A., Sanchez-Vega, Francisco, Smith, Shaleigh A., Antonescu, Cristina R., Rosenbaum, Evan, Shi, Hongyu, Tang, Cerise, Socci, Nicholas D., Rana, Satshil, Gularte-Mérida, Rodrigo, Zehir, Ahmet, Gounder, Mrinal M., Bowler, Timothy G., Luthra, Anisha, Jadeja, Bhumika, Okada, Azusa, Strong, Jonathan A., Stoller, Jake, Chan, Jason E., Chi, Ping, D’Angelo, Sandra P., Dickson, Mark A., Kelly, Ciara M., Keohan, Mary Louise, Movva, Sujana, Thornton, Katherine, Meyers, Paul A., Wexler, Leonard H., Slotkin, Emily K., Glade Bender, Julia L., Shukla, Neerav N., Hensley, Martee L., Healey, John H., La Quaglia, Michael P., Alektiar, Kaled M., Crago, Aimee M., Yoon, Sam S., Untch, Brian R., Chiang, Sarah, Agaram, Narasimhan P., Hameed, Meera R., Berger, Michael F., Solit, David B., Schultz, Nikolaus, Ladanyi, Marc, Singer, Samuel, and Tap, William D.

Published
2022
Full Text
View/download PDF

11. SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas

Author

Rekhtman, Natasha, Montecalvo, Joseph, Chang, Jason C., Alex, Deepu, Ptashkin, Ryan N., Ai, Ni, Sauter, Jennifer L., Kezlarian, Brie, Jungbluth, Achim, Desmeules, Patrice, Beras, Amanda, Bishop, Justin A., Plodkowski, Andrew J., Gounder, Mrinal M., Schoenfeld, Adam J., Namakydoust, Azadeh, Li, Bob T., Rudin, Charles M., Riely, Gregory J., Jones, David R., Ladanyi, Marc, and Travis, William D.

Published
2020
Full Text
View/download PDF

13. Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors

Author

Gounder, Mrinal M, Nayak, Lakshmi, Sahebjam, Solmaz, Muzikansky, Alona, Sanchez, Armando J, Desideri, Serena, Ye, Xiaobu, Ivy, S Percy, Nabors, L Burt, Prados, Michael, Grossman, Stuart, DeAngelis, Lisa M, and Wen, Patrick Y

Subjects
Brain Disorders, Orphan Drug, Cancer, Clinical Research, Neurosciences, Clinical Trials and Supportive Activities, Rare Diseases, Patient Safety, Brain Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Central Nervous System Neoplasms, Clinical Trials, Phase I as Topic, Databases, Factual, Disease Progression, Disease-Free Survival, Female, Humans, Male, Middle Aged, Molecular Targeted Therapy, Patient Selection, Remission Induction, Research Design, Risk Assessment, Risk Factors, Treatment Outcome, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposePatients with high-grade gliomas (HGG) are frequently excluded from first-in-human solid tumor trials because of perceived poor prognosis, excessive toxicities, concomitant drug interactions, and poor efficacy. We conducted an analysis of outcomes from select, single-agent phase I studies in patients with HGG. We compared outcomes to pooled analysis of published studies in solid tumors with various molecular and cytotoxic drugs evaluated as single agents or as combinations.Patient and methodsIndividual records of patients with recurrent HGG enrolled onto Adult Brain Tumor Consortium trials of single-agent, cytotoxic or molecular agents from 2000 to 2008 were analyzed for baseline characteristics, toxicities, responses, and survival.ResultsOur analysis included 327 patients with advanced, refractory HGG who were enrolled onto eight trials involving targeted molecular (n=5) and cytotoxic (n=3) therapies. At enrollment, patients had a median Karnofsky performance score of 90 and median age of 52 years; 62% were men, 63% had glioblastoma, and the median number of prior systemic chemotherapies was one. Baseline laboratory values were in an acceptable range to meet eligibility criteria. Patients were on the study for a median of two cycles (range, ConclusionPatients with HGG who meet standard eligibility criteria may be good candidates for solid tumor phase I studies with single-agent molecular or cytotoxic drugs with favorable preclinical rationale and pharmacokinetic properties in this population.

Published
2015

14. Supplementary Table S3 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

Author

Gleason, Caroline E., primary, Dickson, Mark A., primary, Klein (Dooley), Mary E., primary, Antonescu, Cristina R., primary, Gularte-Mérida, Rodrigo, primary, Benitez, Marimar, primary, Delgado, Juliana I., primary, Kataru, Raghu P., primary, Tan, Mark Wei Yi, primary, Bradic, Martina, primary, Adamson, Travis E., primary, Seier, Kenneth, primary, Richards, Allison L., primary, Palafox, Marta, primary, Chan, Eric, primary, D'Angelo, Sandra P., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Kelly, Ciara M., primary, Chi, Ping, primary, Movva, Sujana, primary, Landa, Jonathan, primary, Crago, Aimee M., primary, Donoghue, Mark T.A., primary, Qin, Li-Xuan, primary, Serra, Violetta, primary, Turkekul, Mesruh, primary, Barlas, Afsar, primary, Firester, Daniel M., primary, Manova-Todorova, Katia, primary, Mehrara, Babak J., primary, Kovatcheva, Marta, primary, Tan, Nguan Soon, primary, Singer, Samuel, primary, Tap, William D., primary, and Koff, Andrew, primary

Published
2024
Full Text
View/download PDF

15. Supplementary Figure S15 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

Author

Gleason, Caroline E., primary, Dickson, Mark A., primary, Klein (Dooley), Mary E., primary, Antonescu, Cristina R., primary, Gularte-Mérida, Rodrigo, primary, Benitez, Marimar, primary, Delgado, Juliana I., primary, Kataru, Raghu P., primary, Tan, Mark Wei Yi, primary, Bradic, Martina, primary, Adamson, Travis E., primary, Seier, Kenneth, primary, Richards, Allison L., primary, Palafox, Marta, primary, Chan, Eric, primary, D'Angelo, Sandra P., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Kelly, Ciara M., primary, Chi, Ping, primary, Movva, Sujana, primary, Landa, Jonathan, primary, Crago, Aimee M., primary, Donoghue, Mark T.A., primary, Qin, Li-Xuan, primary, Serra, Violetta, primary, Turkekul, Mesruh, primary, Barlas, Afsar, primary, Firester, Daniel M., primary, Manova-Todorova, Katia, primary, Mehrara, Babak J., primary, Kovatcheva, Marta, primary, Tan, Nguan Soon, primary, Singer, Samuel, primary, Tap, William D., primary, and Koff, Andrew, primary

Published
2024
Full Text
View/download PDF

16. Data from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

Author

Gleason, Caroline E., primary, Dickson, Mark A., primary, Klein (Dooley), Mary E., primary, Antonescu, Cristina R., primary, Gularte-Mérida, Rodrigo, primary, Benitez, Marimar, primary, Delgado, Juliana I., primary, Kataru, Raghu P., primary, Tan, Mark Wei Yi, primary, Bradic, Martina, primary, Adamson, Travis E., primary, Seier, Kenneth, primary, Richards, Allison L., primary, Palafox, Marta, primary, Chan, Eric, primary, D'Angelo, Sandra P., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Kelly, Ciara M., primary, Chi, Ping, primary, Movva, Sujana, primary, Landa, Jonathan, primary, Crago, Aimee M., primary, Donoghue, Mark T.A., primary, Qin, Li-Xuan, primary, Serra, Violetta, primary, Turkekul, Mesruh, primary, Barlas, Afsar, primary, Firester, Daniel M., primary, Manova-Todorova, Katia, primary, Mehrara, Babak J., primary, Kovatcheva, Marta, primary, Tan, Nguan Soon, primary, Singer, Samuel, primary, Tap, William D., primary, and Koff, Andrew, primary

Published
2024
Full Text
View/download PDF

17. Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy

Author

Kazansky, Yaniv, primary, Cameron, Daniel, additional, Mueller, Helen S., additional, Demarest, Phillip, additional, Zaffaroni, Nadia, additional, Arrighetti, Noemi, additional, Zuco, Valentina, additional, Kuwahara, Yasumichi, additional, Somwar, Romel, additional, Ladanyi, Marc, additional, Qu, Rui, additional, de Stanchina, Elisa, additional, Dela Cruz, Filemon S., additional, Kung, Andrew L., additional, Gounder, Mrinal M., additional, and Kentsis, Alex, additional

Published
2024
Full Text
View/download PDF

18. Supplementary Table S3 from PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis

Author

Hu, Jia, primary, Hameed, Meera R., primary, Agaram, Narasimhan P., primary, Whiting, Karissa A., primary, Qin, Li-Xuan, primary, Villano, Anthony M., primary, O'Connor, Rachael B., primary, Rozenberg, Julian M., primary, Cohen, Sonia, primary, Prendergast, Katherine, primary, Kryeziu, Sara, primary, White, Richard L., primary, Posner, Mitchell C., primary, Socci, Nicholas D., primary, Gounder, Mrinal M., primary, Singer, Samuel, primary, and Crago, Aimee M., primary

Published
2024
Full Text
View/download PDF

19. Data from PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis

Author

Hu, Jia, primary, Hameed, Meera R., primary, Agaram, Narasimhan P., primary, Whiting, Karissa A., primary, Qin, Li-Xuan, primary, Villano, Anthony M., primary, O'Connor, Rachael B., primary, Rozenberg, Julian M., primary, Cohen, Sonia, primary, Prendergast, Katherine, primary, Kryeziu, Sara, primary, White, Richard L., primary, Posner, Mitchell C., primary, Socci, Nicholas D., primary, Gounder, Mrinal M., primary, Singer, Samuel, primary, and Crago, Aimee M., primary

Published
2024
Full Text
View/download PDF

20. Supplementary Data 1 from PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis

Author

Hu, Jia, primary, Hameed, Meera R., primary, Agaram, Narasimhan P., primary, Whiting, Karissa A., primary, Qin, Li-Xuan, primary, Villano, Anthony M., primary, O'Connor, Rachael B., primary, Rozenberg, Julian M., primary, Cohen, Sonia, primary, Prendergast, Katherine, primary, Kryeziu, Sara, primary, White, Richard L., primary, Posner, Mitchell C., primary, Socci, Nicholas D., primary, Gounder, Mrinal M., primary, Singer, Samuel, primary, and Crago, Aimee M., primary

Published
2024
Full Text
View/download PDF

21. Immune checkpoint inhibitor response in sarcomas associates with immune infiltrates and increased expression of transposable elements and viral response pathways

Author

Nacev, Benjamin A., primary, Bradic, Martina, additional, Woo, Hyung Jun, additional, Richards, Allison L., additional, Kelly, Ciara M., additional, Dickson, Mark A., additional, Gounder, Mrinal M., additional, Keohan, Mary L., additional, Chi, Ping, additional, Movva, Sujana, additional, Maki, Robert, additional, Slotkin, Emily K., additional, Rosenbaum, Evan, additional, Avutu, Viswatej, additional, Chan, Jason E., additional, Banks, Lauren, additional, Adamson, Travis, additional, Singer, Samuel, additional, Antonescu, Cristina R., additional, Tap, William D., additional, Donoghue, Mark T.A., additional, and D’Angelo, Sandra P., additional

Published
2024
Full Text
View/download PDF

23. A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor

Author

Kelly, Ciara M., Shoushtari, Alexander N., Qin, Li-Xuan, D’Angelo, Sandra P., Dickson, Mark A., Gounder, Mrinal M., Keohan, Mary Louise, Mcfadyen, Chloe, Sjoberg, Ana, Singer, Samuel, DeMatteo, Ronald P., Hwang, Sinchun, Heinemann, M. H., Francis, Jasmine H., Antonescu, Cristina R., Chi, Ping, and Tap, William D.

Published
2019
Full Text
View/download PDF

25. PDGFRβ signaling cooperates with β-catenin to modulate c-Abl and biologic behavior of desmoid-type fibromatosis

Author

Hu, Jia, primary, Hameed, Meera R., additional, Agaram, Narasimhan P., additional, Whiting, Karissa A., additional, Qin, Li-Xuan, additional, Villano, Anthony M., additional, O'Connor, Rachael B., additional, Rozenberg, Julian M., additional, Cohen, Sonia, additional, Prendergast, Katherine, additional, Kryeziu, Sara, additional, White, Richard L., additional, Posner, Mitchell C., additional, Socci, Nicholas D., additional, Gounder, Mrinal M., additional, Singer, Samuel, additional, and Crago, Aimee M., additional

Published
2023
Full Text
View/download PDF

26. Supplementary Data from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, primary, Bradic, Martina, primary, Kelly, Ciara, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Avutu, Viswatej, primary, Chi, Ping, primary, Thornton, Katherine A., primary, Chan, Jason E., primary, Dickson, Mark A., primary, Donoghue, Mark T.A., primary, Tap, William D., primary, Qin, Li-Xuan, primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

27. TABLE 3 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, primary, Bradic, Martina, primary, Kelly, Ciara, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Avutu, Viswatej, primary, Chi, Ping, primary, Thornton, Katherine A., primary, Chan, Jason E., primary, Dickson, Mark A., primary, Donoghue, Mark T.A., primary, Tap, William D., primary, Qin, Li-Xuan, primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

28. TABLE 4 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, primary, Bradic, Martina, primary, Kelly, Ciara, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Avutu, Viswatej, primary, Chi, Ping, primary, Thornton, Katherine A., primary, Chan, Jason E., primary, Dickson, Mark A., primary, Donoghue, Mark T.A., primary, Tap, William D., primary, Qin, Li-Xuan, primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

29. Data from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, primary, Bradic, Martina, primary, Kelly, Ciara, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Avutu, Viswatej, primary, Chi, Ping, primary, Thornton, Katherine A., primary, Chan, Jason E., primary, Dickson, Mark A., primary, Donoghue, Mark T.A., primary, Tap, William D., primary, Qin, Li-Xuan, primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

30. TABLE 2 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, primary, Bradic, Martina, primary, Kelly, Ciara, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Avutu, Viswatej, primary, Chi, Ping, primary, Thornton, Katherine A., primary, Chan, Jason E., primary, Dickson, Mark A., primary, Donoghue, Mark T.A., primary, Tap, William D., primary, Qin, Li-Xuan, primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

31. TABLE 1 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, primary, Bradic, Martina, primary, Kelly, Ciara, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Avutu, Viswatej, primary, Chi, Ping, primary, Thornton, Katherine A., primary, Chan, Jason E., primary, Dickson, Mark A., primary, Donoghue, Mark T.A., primary, Tap, William D., primary, Qin, Li-Xuan, primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

32. Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, additional, Bradic, Martina, additional, Kelly, Ciara, additional, Movva, Sujana, additional, Nacev, Benjamin A., additional, Gounder, Mrinal M., additional, Keohan, Mary L., additional, Avutu, Viswatej, additional, Chi, Ping, additional, Thornton, Katherine A., additional, Chan, Jason E., additional, Dickson, Mark A., additional, Donoghue, Mark T.A., additional, Tap, William D., additional, Qin, Li-Xuan, additional, and D'Angelo, Sandra P., additional

Published
2023
Full Text
View/download PDF

33. Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

Author

Gleason, Caroline E., primary, Dickson, Mark A., additional, Klein (Dooley), Mary E., additional, Antonescu, Cristina R., additional, Gularte-Mérida, Rodrigo, additional, Benitez, Marimar, additional, Delgado, Juliana I., additional, Kataru, Raghu P., additional, Tan, Mark Wei Yi, additional, Bradic, Martina, additional, Adamson, Travis E., additional, Seier, Kenneth, additional, Richards, Allison L., additional, Palafox, Marta, additional, Chan, Eric, additional, D'Angelo, Sandra P., additional, Gounder, Mrinal M., additional, Keohan, Mary Louise, additional, Kelly, Ciara M., additional, Chi, Ping, additional, Movva, Sujana, additional, Landa, Jonathan, additional, Crago, Aimee M., additional, Donoghue, Mark T.A., additional, Qin, Li-Xuan, additional, Serra, Violetta, additional, Turkekul, Mesruh, additional, Barlas, Afsar, additional, Firester, Daniel M., additional, Manova-Todorova, Katia, additional, Mehrara, Babak J., additional, Kovatcheva, Marta, additional, Tan, Nguan Soon, additional, Singer, Samuel, additional, Tap, William D., additional, and Koff, Andrew, additional

Published
2023
Full Text
View/download PDF

35. Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Author

Samstein, Robert M., Lee, Chung-Han, Shoushtari, Alexander N., Hellmann, Matthew D., Shen, Ronglai, Janjigian, Yelena Y., Barron, David A., Zehir, Ahmet, Jordan, Emmet J., Omuro, Antonio, Kaley, Thomas J., Kendall, Sviatoslav M., Motzer, Robert J., Hakimi, A. Ari, Voss, Martin H., Russo, Paul, Rosenberg, Jonathan, Iyer, Gopa, Bochner, Bernard H., Bajorin, Dean F., Al-Ahmadie, Hikmat A., Chaft, Jamie E., Rudin, Charles M., Riely, Gregory J., Baxi, Shrujal, Ho, Alan L., Wong, Richard J., Pfister, David G., Wolchok, Jedd D., Barker, Christopher A., Gutin, Philip H., Brennan, Cameron W., Tabar, Viviane, Mellinghoff, Ingo K., DeAngelis, Lisa M., Ariyan, Charlotte E., Lee, Nancy, Tap, William D., Gounder, Mrinal M., D’Angelo, Sandra P., Saltz, Leonard, Stadler, Zsofia K., Scher, Howard I., Baselga, Jose, Razavi, Pedram, Klebanoff, Christopher A., Yaeger, Rona, Segal, Neil H., Ku, Geoffrey Y., DeMatteo, Ronald P., Ladanyi, Marc, Rizvi, Naiyer A., Berger, Michael F., Riaz, Nadeem, Solit, David B., Chan, Timothy A., and Morris, Luc G. T.

Published
2019
Full Text
View/download PDF

36. Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials

Author

Yokota, Tomoya, Bendell, Johanna, LoRusso, Patricia, Tsushima, Takahiro, Desai, Ved, Kenmotsu, Hirotsugu, Watanabe, Junichiro, Ono, Akira, Murugesan, Bhavani, Silva, Joseph, Naito, Tateaki, Greenberg, Jonathan, Kumar, Prasanna, Wang, Yibin, Jikoh, Takahiro, Shiga, Ryota, Hyman, David M., Ho, Alan Loh, Spriggs, David R., Schwartz, Gary K., and Gounder, Mrinal M.

Published
2018
Full Text
View/download PDF

37. Data from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Author

LoRusso, Patricia, primary, Yamamoto, Noboru, primary, Patel, Manish R., primary, Laurie, Scott A., primary, Bauer, Todd M., primary, Geng, Junxian, primary, Davenport, Teffany, primary, Teufel, Michael, primary, Li, Jian, primary, Lahmar, Mehdi, primary, and Gounder, Mrinal M., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 1 from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Author

LoRusso, Patricia, primary, Yamamoto, Noboru, primary, Patel, Manish R., primary, Laurie, Scott A., primary, Bauer, Todd M., primary, Geng, Junxian, primary, Davenport, Teffany, primary, Teufel, Michael, primary, Li, Jian, primary, Lahmar, Mehdi, primary, and Gounder, Mrinal M., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure 2 from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Author

LoRusso, Patricia, primary, Yamamoto, Noboru, primary, Patel, Manish R., primary, Laurie, Scott A., primary, Bauer, Todd M., primary, Geng, Junxian, primary, Davenport, Teffany, primary, Teufel, Michael, primary, Li, Jian, primary, Lahmar, Mehdi, primary, and Gounder, Mrinal M., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Methods from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Author

LoRusso, Patricia, primary, Yamamoto, Noboru, primary, Patel, Manish R., primary, Laurie, Scott A., primary, Bauer, Todd M., primary, Geng, Junxian, primary, Davenport, Teffany, primary, Teufel, Michael, primary, Li, Jian, primary, Lahmar, Mehdi, primary, and Gounder, Mrinal M., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table 2 from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Author

LoRusso, Patricia, primary, Yamamoto, Noboru, primary, Patel, Manish R., primary, Laurie, Scott A., primary, Bauer, Todd M., primary, Geng, Junxian, primary, Davenport, Teffany, primary, Teufel, Michael, primary, Li, Jian, primary, Lahmar, Mehdi, primary, and Gounder, Mrinal M., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Table 1 from The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Author

LoRusso, Patricia, primary, Yamamoto, Noboru, primary, Patel, Manish R., primary, Laurie, Scott A., primary, Bauer, Todd M., primary, Geng, Junxian, primary, Davenport, Teffany, primary, Teufel, Michael, primary, Li, Jian, primary, Lahmar, Mehdi, primary, and Gounder, Mrinal M., primary

Published
2023
Full Text
View/download PDF

43. The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Author

LoRusso, Patricia, primary, Yamamoto, Noboru, additional, Patel, Manish R., additional, Laurie, Scott A., additional, Bauer, Todd M., additional, Geng, Junxian, additional, Davenport, Teffany, additional, Teufel, Michael, additional, Li, Jian, additional, Lahmar, Mehdi, additional, and Gounder, Mrinal M., additional

Published
2023
Full Text
View/download PDF

44. Supplementary Data 2 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma

Author

Kelly, Ciara M., primary, Qin, Li-Xuan, primary, Whiting, Karissa A., primary, Richards, Allison L., primary, Avutu, Viswatej, primary, Chan, Jason E., primary, Chi, Ping, primary, Dickson, Mark A., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Rosenbaum, Evan, primary, Adamson, Travis, primary, Singer, Samuel, primary, Bartlett, Edmund K., primary, Crago, Aimee M., primary, Yoon, Sam S., primary, Hwang, Sinchun, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Tap, William D., primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

45. A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with advanced sarcoma: Results of expansion cohorts.

Author

Kelly, Ciara Marie, primary, Avutu, Viswatej, additional, Chi, Ping, additional, Dickson, Mark Andrew, additional, Gounder, Mrinal M., additional, Keohan, Mary Louise, additional, Movva, Sujana, additional, Rosenbaum, Evan, additional, Cordover, Emma, additional, Ariyan, Charlotte Eielson, additional, Bartlett, Edmund, additional, Crago, Aimee Marie, additional, Singer, Samuel, additional, Antonescu, Cristina R., additional, Hwang, Sinchun, additional, Erinjeri, Joseph Patrick, additional, Seier, Kenneth, additional, Qin, Li-Xuan, additional, Tap, William D., additional, and D'Angelo, Sandra P., additional

Published
2023
Full Text
View/download PDF

46. Supplementary Data 1 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma

Author

Kelly, Ciara M., primary, Qin, Li-Xuan, primary, Whiting, Karissa A., primary, Richards, Allison L., primary, Avutu, Viswatej, primary, Chan, Jason E., primary, Chi, Ping, primary, Dickson, Mark A., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Rosenbaum, Evan, primary, Adamson, Travis, primary, Singer, Samuel, primary, Bartlett, Edmund K., primary, Crago, Aimee M., primary, Yoon, Sam S., primary, Hwang, Sinchun, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Tap, William D., primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Data 3 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma

Author

Kelly, Ciara M., primary, Qin, Li-Xuan, primary, Whiting, Karissa A., primary, Richards, Allison L., primary, Avutu, Viswatej, primary, Chan, Jason E., primary, Chi, Ping, primary, Dickson, Mark A., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Rosenbaum, Evan, primary, Adamson, Travis, primary, Singer, Samuel, primary, Bartlett, Edmund K., primary, Crago, Aimee M., primary, Yoon, Sam S., primary, Hwang, Sinchun, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Tap, William D., primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

48. Data from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma

Author

Kelly, Ciara M., primary, Qin, Li-Xuan, primary, Whiting, Karissa A., primary, Richards, Allison L., primary, Avutu, Viswatej, primary, Chan, Jason E., primary, Chi, Ping, primary, Dickson, Mark A., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Rosenbaum, Evan, primary, Adamson, Travis, primary, Singer, Samuel, primary, Bartlett, Edmund K., primary, Crago, Aimee M., primary, Yoon, Sam S., primary, Hwang, Sinchun, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Tap, William D., primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Tables from First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

Author

Tabernero, Josep, primary, Shapiro, Geoffrey I., primary, LoRusso, Patricia M., primary, Cervantes, Andres, primary, Schwartz, Gary K., primary, Weiss, Glen J., primary, Paz-Ares, Luis, primary, Cho, Daniel C., primary, Infante, Jeffrey R., primary, Alsina, Maria, primary, Gounder, Mrinal M., primary, Falzone, Rick, primary, Harrop, Jamie, primary, White, Amy C. Seila, primary, Toudjarska, Iva, primary, Bumcrot, David, primary, Meyers, Rachel E., primary, Hinkle, Gregory, primary, Svrzikapa, Nenad, primary, Hutabarat, Renta M., primary, Clausen, Valerie A., primary, Cehelsky, Jeffrey, primary, Nochur, Saraswathy V., primary, Gamba-Vitalo, Christina, primary, Vaishnaw, Akshay K., primary, Sah, Dinah W.Y., primary, Gollob, Jared A., primary, and Burris, Howard A., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Table 1 from Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor

Author

Slotkin, Emily K., primary, Bowman, Anita S., primary, Levine, Max F., primary, Dela Cruz, Filemon, primary, Coutinho, Diego F., primary, Sanchez, Glorymar I., primary, Rosales, Nestor, primary, Modak, Shakeel, primary, Tap, William D., primary, Gounder, Mrinal M., primary, Thornton, Katherine A., primary, Bouvier, Nancy, primary, You, Daoqi, primary, Gundem, Gunes, primary, Gerstle, Justin T., primary, Heaton, Todd E., primary, LaQuaglia, Michael P., primary, Wexler, Leonard H., primary, Meyers, Paul A., primary, Kung, Andrew L., primary, Papaemmanuil, Elli, primary, Zehir, Ahmet, primary, Ladanyi, Marc, primary, and Shukla, Neerav, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results